Dissection of stromal and cancer cell-derived signals in melanoma xenografts before and after treatment with DMXAA

British Journal of Cancer

Volumn 106, Issue 6, 2012, Pages 1134-1147

  Henare, K ^a   Wang, L ^b   Wang, L C ^a   Thomsen, L ^a   Tijono, S ^a   Chen, C J ^c   Winkler, S ^c   Dunbar, P R ^b,c   Print, C ^b   Ching, L M ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

cytokines; DMXAA; melanoma; stroma; xenografts

Indexed keywords

CYTOKINE; VADIMEZAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; CANCER INHIBITION; CONTROLLED STUDY; GENE EXPRESSION; LEUKOCYTE COUNT; MELANOMA; MELANOMA CELL; MOUSE; NECROSIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CYTOKINES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKOUT TECHNIQUES; GENE REGULATORY NETWORKS; HOMEODOMAIN PROTEINS; HUMANS; LEUKOCYTES; MACROPHAGES; MELANOMA; MICE; MICE, KNOCKOUT; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; STROMAL CELLS; TRANSCRIPTION, GENETIC; TUMOR BURDEN; UP-REGULATION; XANTHONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863288486     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.63     Document Type: Article

References (50)

1. Angel CE, Chen CJJ, Horlacher OC, Winkler S, John T, Browning J, MacGregor D, Cebon J, Dunbar PR (2009) Distinctive localization of antigen-presenting cells in human lymph nodes. Blood 113(6): 1257-1267
2. Angel CE, George E, Brooks AES, Ostrovsky LL, Brown TLH, Dunbar PR (2006) Cutting edge: CD1a+ antigen-presenting cells in human dermis respond rapidly to CCR7 ligands. J Immunol 176(10): 5730-5734
3. Bibby MC, Phillips RM, Double JA, Pratesi G (1991) Anti-tumour activity of flavone acetic acid (NSC 347512) in mice-influence of immune status. Br J Cancer 63(1): 57-62
4. Brauer R, Wang LCS, Woon ST, Bridewell DJA, Henare K, Malinger D, Palmer BD, Vogel SN, Kieda C, Tijono SM, Ching LM (2010) Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action. Neoplasia 12(9): 755-765
5. Ch'ng S, Tan S (2009) Genetics, cellular biology and tumor microenvironment of melanoma. Front Biosci 14: 918-928
6. Ching L-M, Cao Z, Kieda C, Zwain S, Jameson MB, Baguley BC (2002) Induction of endothelial cell apoptosis by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 86: 1937-1942
7. Ching L-M, Goldsmith D, Joseph WR, Korner H, Sedgwick JD, Baguley BC (1999a) Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice. Cancer Res 59: 3304-3307 (Pubitemid 29334480)
8. Ching L-M, Young HA, Eberly K, Yu C-R (1999b) Induction of STAT and NFkB activation by the antitumor agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line. Biochem Pharmacol 58: 1173-1181 (Pubitemid 29381518)
9. Ching L-M, Zwain S, Baguley BC (2004) Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice. Br J Cancer 90(4): 906-910 (Pubitemid 38406605)
10. Ching LM, Joseph WR, Baguley BC (1992) Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br J Cancer 66: 128-130
11. Ching LM, Wang LC, Brauer R, Bridewell DJA, Henare K, Palmer BD (2010) Labeling of oxidizable proteins with a photoactivatable analog of the antitumor agent DMXAA: evidence for redox signaling in its mode of action [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 17-21 April 2010. AACR: Washington, DC; Philadelphia, PA, (abstract 24)
12. Creighton C, Kuick R, Misek D, Rickman D, Brichory F, Rouillard J-M, Omenn G, Hanash S (2003) Profiling of pathway-specific changes in gene expression following growth of human cancer cell lines transplanted into mice. Genome Biol 4(7): R46
13. Creighton CJ, Bromberg-White JL, Misek DE, Monsma DJ, Brichory F, Kuick R, Giordano TJ, Gao W, Omenn GS, Webb CP, Hanash SM (2005) Analysis of tumor-host interactions by gene expression profiling of lung adenocarcinoma xenografts identifies genes involved in tumor formation. Mol Cancer Res 3(3): 119-129 (Pubitemid 40524895)
14. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM (2009) Polarization of tumor-associated neutrophil phenotype by TGF-[beta]: 'N1' vs 'N2' TAN. Cancer Cell 16(3): 183-194
15. Gabra H, Jameson M (2007) Update of phase II study of DMXAA (AS1404) combined with carboplatin and paclitaxel in recurrent ovarian cancer. Eur J Cancer Suppl 5(4): 319-319
16. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, Kolesnick R (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300: 1155-1159 (Pubitemid 36583102)
17. Ge R, Rajeev V, Ray P, Lattime E, Rittling S, Medicherla S, Protter A, Murphy A, Chakravarty J, Dugar S, Schreiner G, Barnard N, Reiss M (2006) Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-b type I receptor kinase In vivo. Clin Cancer Res 12(14): 4315-4330
18. Harrell J, Dye W, Harvell D, Sartorius C, Horwitz K (2008) Contaminating cells alter gene signatures in whole organ vs laser capture microdissected tumors: a comparison of experimental breast cancers and their lymph node metastases. Clin Exp Metastasis 25(1): 81-88 (Pubitemid 351191228)
19. Hull ML, Escareno CR, Godsland JM, Doig JR, Johnson CM, Phillips SC, Smith SK, Tavare S, Print CG, Charnock-Jones DS (2008) Endometrialperitoneal interactions during endometriotic lesion establishment. Am J Pathol 173(3): 700-715
20. Ilkovitch D, Lopez DM (2008) Immune modulation by melanoma-derived factors. Exp Dermatol 17: 977-985
21. Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, Burdick MD, Strieter RM, Ching L-M, Kaiser LR, Albelda SM (2005) Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma. Cancer Res 65(24): 11752-11761 (Pubitemid 41821737)
22. Joseph WR, Cao Z, Mountjoy KG, Marshall ES, Baguley BC, Ching L-M (1999) Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy. Cancer Res 59: 633-638 (Pubitemid 29076061)
23. Kalluri R (2003) Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3(6): 422-433 (Pubitemid 37328846)
24. Kanwar JR, Kanwar RK, Pandey S, Ching LM, Krissansen GW (2001) Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Cancer Res 61(5): 1948-1956 (Pubitemid 32692012)
25. Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X, Yu L, Ross J, Korsisaari N, Cao T, Bou-Reslan H, Kallop D, Weimer R, Ludlam MJC, Kaminker JS, Modrusan Z, van Bruggen N, Peale FV, Carano R, Meng YG, Ferrara N (2010) Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc Natl Acad Sci USA 107(50): 21248-21255
26. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR (1998) Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 78(4): 439-445 (Pubitemid 28360629)
27. Lienard D, Ewalenko P, Delmotte JJ, Renard N, Lejeune FJ (1992) High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 10(1): 52-60
28. Lloyd CM, Phillips ARJ, Cooper GJS, Dunbar PR (2008) Three-colour fluorescence immunohistochemistry reveals the diversity of cells staining for macrophage markers in murine spleen and liver. J Immunol Methods 334: 70-81
29. Marshall ES, Holdaway KM, Shaw JH, Finlay GJ, Mathews JH, Baguley BC (1993) Anticancer drug sensitivity profiles of new and established melanoma cell lines. Oncol Res 5: 301-309 (Pubitemid 24113422)
30. McKeage MJ, Von Pawel J, Reck M, Jameson MB, Rosenthal MA, Sullivan R, Gibbs D, Mainwaring PN, Serke M, Lafitte JJ, Chouaid C, Freitag L, Quoix E (2008) Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Br J Cancer 99(12): 2006-2012
31. Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, Kirkwood JM (2006) Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol 24(19): 3164-3171 (Pubitemid 46638955)
32. Nam J-S, Terabe M, Mamura M, Kang M-J, Chae H, Stuelten C, Kohn E, Tang B, Sabzevari H, Anver MR, Lawrence S, Danielpour D, Lonning S, Berzofsky JA, Wakefield LM (2008) An anti-transforming growth factor b antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res 68(10): 3835-3843
33. Palmer BD, Henare K, Woon S-T, Sutherland R, Reddy C, Wang L-CS, Kieda C, Ching L-M (2007) Synthesis and biological activity of azido analogues of 5,6-dimethylxanthenone-4-acetic acid for use in photoaffinity Labeling. J Med Chem 50(16): 3757-3764 (Pubitemid 47292039)
34. Parkins CS, Holder AL, Hill SA, Chaplin DJ, Tozer GM (2000) Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer 83(6): 811-816
35. Parmiani G, Castelli C, Rivoltini L, Casati C, Tully GA, Novellino L, Patuzzo A, Tosi D, Anichini A, Santinami M (2003) Immunotherapy of melanoma. Sem Cancer Biol 13(6): 391-400 (Pubitemid 38156130)
36. Pili R, Rosenthal MA, Mainwaring PN, Van Hazel G, Srinivas S, Dreicer R, Goel S, Leach J, Wong S, Clingan P (2010) Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clin Cancer Res 16(10): 2906-2914
37. Rewcastle GW, Atwell GJ, Zhuang L, Baguley BC, Denny WA (1991) Potential antitumour agents. 61. Structure-activity relationships for in vivo colon 38 activity among disusbstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34(1): 217-221
38. Roberts ZJ, Ching L-M, Vogel SN (2008) IFN-b-dependent inhibition of tumor growth by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). J Interferon Cytokine Res 28(3): 133-139 (Pubitemid 351380153)
39. Roberts ZJ, Goutagny N, Perera P-Y, Kato H, Kumar H, Kawai T, Akira S, Savan R, van Echo D, Fitzgerald KA, Young HA, Ching L-M, Vogel SN (2007) The chemotherapeutic agent DMXAA potently and specifically activates the TBK1-IRF-3 signaling axis. J Exp Med 204(7): 1559-1569 (Pubitemid 47049627)
40. Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J (2005) Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23(4): 741-750 (Pubitemid 46224173)
41. Seshadri M, Ciesielski MJ (2009) MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas. J Cereb Blood Flow Metab 29(8): 1373-1382
42. Seshadri M, Mazurchuk R, Spernyak JA, Bhattacharya A, Rustum YM, Bellnier DA (2006) Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4- acetic acid against human head and neck carcinoma xenografts. Neoplasia 8(7): 534-542 (Pubitemid 44061308)
43. Shaked Y, Tang T, Woloszynek J, Daenen LG, Man S, Xu P, Cai S-R, Arbeit JM, Voest EE, Chaplin DJ, Smythe J, Harris A, Nathan P, Judson I, Rustin G, Bertolini F, Link DC, Kerbel RS (2009) Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Res 69(19): 7524-7528
44. Smith CL, Dunbar PR, Mirza F, Palmowski MJ, Shepherd D, Gilbert SC, Coulie P, Schneider J, Hoffman E, Hawkins R, Harris AL, Cerundolo V (2005) Recombinant modified vaccinia Ankara primes functionally activated CTL specific for a melanoma tumor antigen epitope in melanoma patients with a high risk of disease recurrence. Int J Cancer 113(2): 259-266 (Pubitemid 39628316)
45. van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G, Huber H, Eferl R, Beug H, Dolznig H, Mikulits W (2009) Hepatic tumor-stroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 28(45): 4022-4033
46. Voloshin T, Gingis-Velitski S, Bril R, Benayoun L, Munster M, Milsom C, Man S, Kerbel RS, Shaked Y (2011) G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. Blood 118(12): 3426-3435
47. Wang L-CS, Thomsen L, Sutherland R, Reddy CB, Tijono SM, Chen C-JJ, Angel CE, Dunbar PR, Ching L-M (2009) Neutrophil influx and chemokine production during the early phases of the antitumor response to the vascular disrupting Agent DMXAA (ASA404). Neoplasia 11(8): 793-803
48. Wang LC, Woon S-T, Baguley BC, Ching LM (2006) Inhibition of DMXAAinduced tumor necrosis factor production in murine splenocyte cultures by NF-kappa-b inhibitors. Oncol Res 16(1): 1-14 (Pubitemid 44195045)
49. Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Di Serio C, Naldini L, De Palma M, Tozer GM, Lewis CE (2011) TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J Clin Invest 121(5): 1969-1973
50. Woon S-T, Zwain S, Schooltink MA, Newth A, Baguley BC, Ching L-M (2003) NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Eur J Cancer 39(8): 1176-1183 (Pubitemid 36555878)